# RELIANCE

Source: https://onco.cc/trials/reliance/  
OnCo record `reliance` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The trial that made relma-cel the first CAR-T developed and manufactured in China to be approved, with three quarters of patients responding.

## Summary

59 patients treated (Cancer Medicine 2021): objective response 75.9%, complete response 51.7%, with grade 3 or higher cytokine release syndrome in about 5% and neurotoxicity in about 3%, a favourable profile consistent with the 4-1BB construct shared with lisocabtagene maraleucel. Basis of NMPA approval in September 2021.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-10
- Tags: china
- Phase: 2
- Setting: Relapsed or refractory large B-cell lymphoma after two or more lines, China: single-arm pivotal study of relmacabtagene autoleucel at two dose levels
- Sponsor: JW Therapeutics
- Enrolled: 59
- Result: ORR 75.9%, CR 51.7%.
- Outcomes: Objective response rate: Relma-cel (both dose levels) 75.9%

## Sources

- Cancer Med 2021: https://doi.org/10.1002/cam4.3686

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- drugs: [Relmacabtagene autoleucel](https://onco.cc/drugs/relmacabtagene-autoleucel/)
- companies: [JW Therapeutics](https://onco.cc/companies/jw-therapeutics/)
- key papers: [Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China](https://onco.cc/key-papers/paper-ying-cancer-med/)
- ideas: [In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma](https://onco.cc/ideas/idea-reg-in-vivo-cart-off-the-shelf-vial/), [Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route](https://onco.cc/ideas/idea-reg-non-viral-cart-manufacturing/)
- roadmaps: [Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation](https://onco.cc/roadmaps/global-access-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/reliance.json